NEOS Investment Management LLC Buys 904 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

NEOS Investment Management LLC grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 14.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,014 shares of the company's stock after acquiring an additional 904 shares during the period. NEOS Investment Management LLC's holdings in IDEXX Laboratories were worth $2,900,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. WINTON GROUP Ltd bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $6,408,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in IDEXX Laboratories by 8.3% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 144,011 shares of the company's stock worth $59,841,000 after buying an additional 11,056 shares during the period. Korea Investment CORP boosted its holdings in IDEXX Laboratories by 1.5% in the fourth quarter. Korea Investment CORP now owns 60,917 shares of the company's stock worth $25,186,000 after acquiring an additional 880 shares in the last quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $455,000. Finally, Florida Financial Advisors LLC increased its holdings in shares of IDEXX Laboratories by 26.7% during the fourth quarter. Florida Financial Advisors LLC now owns 850 shares of the company's stock valued at $351,000 after acquiring an additional 179 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on IDXX shares. Piper Sandler boosted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Barclays increased their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Bank of America lifted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Leerink Partners initiated coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price target for the company. Finally, Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $533.75.

IDEXX Laboratories Stock Performance

IDXX traded down $1.82 during midday trading on Tuesday, reaching $418.13. The company had a trading volume of 328,759 shares, compared to its average volume of 582,333. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88. The business has a 50-day moving average price of $437.08 and a two-hundred day moving average price of $442.03. The stock has a market cap of $33.89 billion, a PE ratio of 39.12, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.